Accumulation of inflammatory cells in response to intracutaneous platelet activating factor (Paf-acether) in man
- PMID: 3978036
- DOI: 10.1111/j.1365-2133.1985.tb04855.x
Accumulation of inflammatory cells in response to intracutaneous platelet activating factor (Paf-acether) in man
Abstract
Platelet activating factor (Paf-acether, AGEPC) is a family of ether-linked phospholipids known to be released from a range of inflammatory cell types. In vitro and in experimental animals, it seems to be a mediator of inflammation, and intradermal injection of Paf-acether in man elicits a biphasic inflammatory response, reminiscent of the dual response to allergen in sensitized individuals. In the present study, cutaneous histology was assessed in sequential skin biopsies from six normal volunteers after intradermal injection of 200 or 800 pmol Paf-acether. Paf-acether (200 pmol) induced intravascular accumulation of neutrophils, accompanied by a perivascular mixed cellular infiltrate which was composed predominantly of neutrophils at 4 and 12 hours, and lymphocytes and histiocytes at 24 hours. Control injections of lyso-Paf and normal saline induced no noteworthy histological changes. Paf-acether (800 pmol) resulted in vessel destruction, gross endothelial swelling and a perivascular infiltrate of mononuclear cells and neutrophils, accompanied by occasional evidence of leucocytoclasis. By virtue of its ability to induce inflammatory cell accumulation in human skin, Paf-acether should be considered as a potential mediator of inflammatory disorders such as psoriasis.
Similar articles
-
Inflammatory cell accumulation in response to intracutaneous Paf-acether: a mediator of acute and persistent inflammation?Br J Dermatol. 1985 Jul;113 Suppl 28:133-5. doi: 10.1111/j.1365-2133.1985.tb15642.x. Br J Dermatol. 1985. PMID: 4015978
-
Inflammatory characteristics of PAF-acether in the skin of experimental animals and man.Int J Tissue React. 1985;7(5):363-5. Int J Tissue React. 1985. PMID: 3863807
-
Cutaneous and pulmonary histopathological responses to platelet activating factor (Paf-acether) in the guinea-pig.J Pathol. 1984 Sep;144(1):25-34. doi: 10.1002/path.1711440104. J Pathol. 1984. PMID: 6481526
-
A role for PAF-acether (platelet-activating factor) in platelet-dependent vascular diseases?Circulation. 1985 Oct;72(4):713-7. doi: 10.1161/01.cir.72.4.713. Circulation. 1985. PMID: 3928192 Review.
-
Leukotriene B4 and platelet-activating factor in human skin.Arch Dermatol Res. 1992;284 Suppl 1:S12-7. doi: 10.1007/BF00638234. Arch Dermatol Res. 1992. PMID: 1337424 Review.
Cited by
-
Effect of platelet activating factor (PAF) on the migration of human lymphocytes.Thorax. 1995 Mar;50(3):265-9. doi: 10.1136/thx.50.3.265. Thorax. 1995. PMID: 7660340 Free PMC article.
-
Pharmacological studies on dithranol-induced irritative dermatitis in mice.Arch Dermatol Res. 1989;281(5):362-5. doi: 10.1007/BF00412983. Arch Dermatol Res. 1989. PMID: 2529819
-
The role of eosinophils in asthma.Lung. 1990;168 Suppl:5-17. doi: 10.1007/BF02718107. Lung. 1990. PMID: 2117155 Review.
-
Platelet-activating factor blockade inhibits the T-helper type 17 cell pathway and suppresses psoriasis-like skin disease in K5.hTGF-β1 transgenic mice.Am J Pathol. 2011 Feb;178(2):699-708. doi: 10.1016/j.ajpath.2010.10.008. Am J Pathol. 2011. PMID: 21281802 Free PMC article.
-
Inflammatory responses to intradermal injection of platelet activating factor, histamine and prostaglandin E2 in healthy volunteers: a double blind investigation.Br J Clin Pharmacol. 1987 Dec;24(6):753-61. doi: 10.1111/j.1365-2125.1987.tb03242.x. Br J Clin Pharmacol. 1987. PMID: 2449904 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources